BCC Stock Recent News
BCC LATEST HEADLINES
US Food and Drug Administration (FDA) has accepted the company's Type C meeting request and SKNJCT-003 Phase 2 study has randomized more than 75% of patients Philadelphia, Pennsylvania--(Newsfile Corp. - August 21, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, is pleased to announce, following the acceptance of the Type C meeting request by the United States Food and Drug Administration (the "FDA"), the Company has submitted its queries in writing and expect to receive a response from the FDA before the end of Q3 2025.
Boise Cascade's integration of AI and robotics could drive significant efficiency and EBITDA margin improvements, setting it apart from smaller competitors. The company's integrated production and distribution model, large customer base, and disciplined risk management support stable cash flow and profitability. My DCF model and sector multiples suggest BCC is undervalued, with a fair price of $165/share.
“An In-Depth Strategic Profile of Koninklijke Philips N.V.: Innovation, Global Expansion, and Long-Term Impact” “An In-Depth Strategic Profile of Koninklijke Philips N.V.: Innovation, Global Expansion, and Long-Term Impact”
Boise Cascade Company (NYSE:BCC ) Q2 2025 Earnings Conference Call August 5, 2025 11:00 AM ET Company Participants Chris Forrey - Vice President of Finance & Investor Relations Joanna Barney - Executive Vice President, Building Materials Distribution Kelly E. Hibbs - Senior VP, CFO, Principal Financial & Accounting Officer and Treasurer Nathan R.
Boise Cascade (BCC) came out with quarterly earnings of $1.64 per share, missing the Zacks Consensus Estimate of $1.69 per share. This compares to earnings of $2.84 per share a year ago.
BOISE, Idaho--(BUSINESS WIRE)--Boise Cascade Company ("Boise Cascade," the "Company," "we," or "our") (NYSE: BCC) today reported net income of $62.0 million, or $1.64 per share, on sales of $1.7 billion for the second quarter ended June 30, 2025, compared with net income of $112.3 million, or $2.84 per share, on sales of $1.8 billion for the second quarter ended June 30, 2024. “During the second quarter of 2025, we experienced sequential volume growth driven by seasonally stronger activity, alt.
BOISE, Idaho--(BUSINESS WIRE)--Boise Cascade Company's (Boise Cascade or the Company) (NYSE: BCC) Board of Directors declared a quarterly dividend of $0.22 per share, an increase of $0.01 per share or 5%, to holders of its common stock. The dividend will be paid on September 17, 2025 to stockholders of record on September 2, 2025. Future dividend declarations, including amount per share, record date and payment date, will be made by the board of directors and will depend upon, among other thing.
Boise Cascade (BCC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Graham All Star Value (GASV) strategy identifies top dividend 'dogs' offering high yield and fair pricing, using YCharts' large cap value and Ben Graham screens. Analyst projections suggest the top ten GASV stocks could deliver average net gains of 27.55% by July 2026, with moderate risk. Sixteen of the twenty-one lowest-priced, 'safer' GASV dividend stocks are currently buyable, with dividends exceeding share price for ideal picks.